Evidence map›Paper›PMID 41557115›Full record

ArticleInternational journal of hematology2026

Association of busulfan area under the curve with the development of neurotoxicity in children and adolescents receiving busulfan-containing conditioning regimens for stem cell transplantation.

Kenji Kishimoto, Sayaka Hyodo, Keizo Fukushima, Kei Irie, Shogo Horikawa, Suguru Uemura, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Takeshi Mori and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kenji KishimotoDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan. ken@yacht.ocn.ne.jp.ORCID http://orcid.org/0000-0002-5495-8498
Sayaka HyodoDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Keizo FukushimaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Kei IrieDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Shogo HorikawaDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan.
Suguru UemuraDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Aiko KozakiDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Atsuro SaitoDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Toshiaki IshidaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Takeshi MoriDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Shoji FukushimaDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although several studies suggest that higher busulfan exposure is associated with neurotoxicity, research on the relevance of pharmacokinetic parameters is limited. The aim of this study was to explore the impact of busulfan area under the concentration-time curve (AUC) on the development of neurological complications in children and adolescents receiving busulfan-containing conditioning regimens. Patients aged 0-20 years who received a busulfan-based regimen at our hospital between June 2017 and May 2024 were analyzed. The primary outcome measure was the incidence of neurological complications within 7 days of starting busulfan. A total of 36 consecutive patients were analyzed. Median busulfan AUC across 96 h (AUC96) was 86.3 (interquartile range 73.6-100.8) mg × h/L. Overall, 13 (36%) patients developed neurological complications, including 2 patients with grade 3 seizures. The AUC96 cut-off value was set at 80.0 mg × h/L (sensitivity 85%, specificity 57%, area under the receiver-operating characteristic curve 0.71). A higher incidence of neurological complications was observed in the AUC96 > 80.0 mg × h/L group than in the AUC96 ≤ 80.0 mg × h/L group (50% vs. 14%, P = 0.033). These results suggest that a higher busulfan AUC96 may be associated with an increased risk of neurological complications.

Indexed as

BusulfanHematopoietic Stem Cell TransplantationNeurotoxicity SyndromesTransplantation ConditioningAdolescentArea Under CurveChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleYoung AdultBusulfanBusulfanConditioningNeurotoxicityPharmacokineticsStem cell transplantation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.